Targeting HPV: The Therapeutic Promise of EZH2 Inhibition #TopTeachers
Human papillomavirus (HPV) remains one of the most prevalent viral infections worldwide and is a leading cause of multiple cancers, including cervical, anal, oropharyngeal, and other anogenital malignancies. High-risk HPV types, particularly HPV-16 and HPV-18, are strongly associated with the development of cervical cancer. According to the World Health Organization , cervical cancer is among the most common cancers affecting women globally, especially in low- and middle-income countries. While prophylactic vaccines have significantly reduced HPV infection rates, they do not eliminate established infections or existing HPV-driven cancers. Therefore, innovative therapeutic strategies are urgently needed. One promising avenue is targeting epigenetic regulators such as Enhancer of Zeste Homolog 2 (EZH2), a histone methyltransferase implicated in tumor progression and viral oncogenesis. EZH2 is the catalytic component of the Polycomb Repressive Complex 2 (PRC2), which mediates the tr...